52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Immutep Says Ulcerative Colitis Phase II Study Of GSK2831781 Discontinued
Viiv Healthcare Announces FDA Approval Of Cabenuva For HIV Treatment
Biondvax Announces Appointment Of Amir Reichman As New CEO
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
G S K House, 980 Great West Road
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Emma N. Walmsley
Chief Executive Officer, Executive Director
Iain James Mackay
Chief Financial Officer, Executive Director
Roger G. Connor
President - Vaccines
Chief Executive Officer - GSK Consumer Healthcare
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
U.S. President Joe Biden will sign orders to speed delivery of coronavirus stimulus checks and food aid, while Europe's vaccination drive was dealt another blow when AstraZeneca said initial deliveries to the region will fall short of the targeted volumes.
The U.S. Food and Drug Administration on Thursday approved a long-acting HIV injection from British drugmaker GlaxoSmithKline's HIV treatment division, ViiV Healthcare.
Merck KGaA's drug development programme has suffered a setback with its most important experimental drug, cancer treatment bintrafusp alfa, failing early in its lead trial.
Germany's Merck KGaA said the most important clinical trial testing its cancer drug hopeful bintrafusp alfa, which it is co-developing with GlaxoSmithKline, would be stopped because the treatment does not appear to work.
The U.S. Food and Drug Administration has rejected GlaxoSmithKline's request to weigh in on a key question in lawsuits by women who say the drugmaker failed to warn them that taking the anti-nausea drug Zofran during pregnancy can cause birth defects.
* GSK AND NOVARTIS ANNOUNCE COLLABORATION TO SUPPORT SCIENTIFIC RESEARCH INTO GENETIC DIVERSITY IN AFRICA
* GSK PRESENTS POSITIVE EFFICACY DATA OF DOSTARLIMAB IN MISMATCH REPAIR-DEFICIENT (DMMR) SOLID CANCERS AT ASCO GASTROINTESTINAL CANCERS SYMPOSIUM
* GSK - VIIV HEALTHCARE RECEIVES EU MARKETING AUTHORISATION FOR FIRST-EVER DISPERSIBLE-TABLET FORMULATION OF DOLUTEGRAVIR, TIVICAY
British drugmaker GSK and U.S.-based Vir Biotechnology will evaluate a second antibody-based treatment in patients with mild to moderate COVID-19 in an early- to mid-stage trial, the companies said on Tuesday.
* VIR BIOTECHNOLOGY AND GSK ANNOUNCE NHS-SUPPORTED AGILE STUDY TO EVALUATE VIR-7832 IN EARLY TREATMENT OF COVID-19
* ELIGO BIOSCIENCE SA - ANNOUNCED THAT IT HAS ENTERED INTO A RESEARCH AND OPTION AGREEMENT WITH GLAXOSMITHKLINE Source text for Eikon: Further company coverage:
A federal judge on Friday tossed a slew of claims against major drugmakers in multidistrict litigation over recalled heartburn drug Zantac, finding them preempted by the federal Food, Drug and Cosmetic Act.
Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise U.S. prices on more than 300 drugs in the United States on Jan. 1, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.
Drugmakers including Pfizer Inc , Sanofi SA, and GlaxoSmithKline Plc plan to raise U.S. prices on more than 300 drugs in the United States on Jan. 1, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.
* GLAXOSMITHKLINE PLC - VIIV FIRST LONG-ACTING HIV REGIMEN APPROVED IN EU
Japan's Sosei Group Corp said late on Sunday it agreed with GlaxoSmithKline to collaborate on developing treatments for some digestive tract illnesses caused by immune disorders.
* GSK - GSK AND AHREN ANNOUNCE CO-LED SERIES A INVESTMENT IN ADRESTIA
Dozens of professors at major universities are urging the full Federal Circuit U.S. Court of Appeals to review an October panel decision that Teva Pharmaceutical Industries Ltd's generic version of GlaxoSmithKline PLC's heart drug Coreg infringed a GSK patent, even though...
A lawyer for women suing GlaxoSmithKline for failing to warn that taking the anti-nausea drug Zofran during pregnancy can cause birth defects argued on Wednesday that the U.S. Food and Drug Administration's rejection of a warning label does not moot their cases.
Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people, delaying its launch to late next year and marking a setback in the global fight against the pandemic.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.